CLAIMS

1. A pharmaceutical composition including about 2.5mg loratadine, or a corresponding amount in the form of a suitable salt thereof, together with about 8 to about 10mg of 3-hydroxy-α-[(methylamino)methyl]benzene- methanol (phenylephrine) free base or a corresponding amount of a suitable salt thereof, for use in a method of treating upper respiratory/mucosal congestion by administering to a patient four times a day.

2. A composition according to claim 1, where the phenylephrine is present as a hydrochloride salt.

3. A composition according to claim 2, including 10 to 12.2 mg of the hydrochloride salt.

4. A composition according to claim 1, 2 or 3, which is in a solid dosage form.

5. The use of about 2.5mg loratadine, or a corresponding amount of a suitable salt thereof, together with about 8 to about 10mg of 3-hydroxy- α -[(methyl-amino)methyl]benzenemethanol (phenylephrine) free base, or a corresponding amount of a suitable salt thereof, in the manufacture of a medicament for the treatment of upper respiratory/mucosal congestion, wherein the medicament is for administration to a patient four times a day.

6. The use according to claim 5, comprising the use of 8 to 10mg of phenylephrine, or a corresponding amount in the form of suitable salt thereof, in the manufacture of the medicament.

7. The use according to claim 6, where the medicament is manufactured for administration qid.

8. The use according to claim 6 or claim 7, where the phenylephrine is in a salt form.

9. The use according to claim 8, where the phenylephrine salt is the hydrochloride salt.

10. A pharmaceutical composition according to any one of claims 1- to 4, or a use according to any one of claims 5 to 9, where the pharmaceutical composition/medicament includes pharmaceutically acceptable non-active excipients and/or carriers.

11. A pharmaceutical composition or a use according to claim 10, where the pharmaceutical composition / medicament is a pill, capsule or tablet.

12. A pharmaceutical composition or use according to claim 11, wherein the composition / medicament comprises 10.00mg phenylephrine hydrochloride, 2.50mg loratadine, 180.40mg lactose, 140.00mg maize starch, 10.365mg pregelatinised starch, 0.20mg lake of quinoline yellow, 0.40mg sodium metabisulphite, 0.14mg disodium EDTA, 3.00mg talc, and 3.00mg magnesium stearate

13. The use of loratadine, or a suitable salt thereof, together with 3-hydroxy- α -[(methyl-amino)methyl]benzenemethanol (phenylephrine) free base, or a suitable salt thereof, in the manufacture of a syrup medicament for the treatment of upper respiratory/mucosal congestion, wherein the medicament is for administering 2.5mg loratadine, or a corresponding amount of a suitable salt thereof, together with about 8 to about 10mg of 3-hydroxy- α -[(methyl-amino)methyl]benzenemethanol (phenylephrine) free base, or a corresponding amount of a suitable salt thereof, to a patient four times a day.

14. A use according to claim 13, where the phenylephrine is in the form of a hydrochloride salt.